Iloperidone (Fanapt) vs Loxapine (Adasuve)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Iloperidone (Fanapt)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Partial signal

NCT00254202 · Phase 3 · completed

This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).

Next expected readout: November 2027 · NCT06961968 (registry estimate)

Reported efficacy

Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)

Result source: NCT00254202

Loxapine (Adasuve)

Marketed by Lee's Pharmaceutical and partners

Phase 3 in Schizophreniasmall molecule
Reliable signal

NCT00628589 · Phase 3 · completed

The trial randomly assigned 344 participants to inhaled loxapine 5 mg, loxapine 10 mg, or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical agitation measure was significantly improved with both loxapine doses compared with placebo (p=0.0004 and p<0.0001).

Reported efficacy

Change in PANSS-EC From Baseline (Baseline and 2 hours): Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92) (met)

Result source: NCT00628589

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointIloperidone (Fanapt)Loxapine (Adasuve)
PANSS total, change-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
—Not reported
CGI-S, change—Trial running · NCT06961968—Not reported
PANSS response—Trial running · NCT06961968—Not reported
PSP, change—Trial running · NCT06961968—Not reported
Relapse (% of patients)—Trial running · NCT06961968—Not reported

PANSS total, change

Iloperidone (Fanapt)
-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
Loxapine (Adasuve)
—Not reported

CGI-S, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Loxapine (Adasuve)
—Not reported

PANSS response

Iloperidone (Fanapt)
—Trial running · NCT06961968
Loxapine (Adasuve)
—Not reported

PSP, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Loxapine (Adasuve)
—Not reported

Relapse (% of patients)

Iloperidone (Fanapt)
—Trial running · NCT06961968
Loxapine (Adasuve)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Iloperidone (Fanapt): 4 of 4 rows · Loxapine (Adasuve): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIloperidone (Fanapt)Loxapine (Adasuve)
Dropout rate
34.6%a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
51.3%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
30.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
31.5%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
18.8%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
12.5%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
13.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
2.7%10 mgb
NCT00628589 · Phase 3 · monotherapy
show 8 more results
1.7%5 mg
NCT00628589 · Phase 3 · monotherapy
2.4%10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%1.25 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%0.625 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
14.5%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
10.4%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
15%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—10 mgb
NCT00628589 · Phase 3 · monotherapy
show 8 more results
—5 mg
NCT00628589 · Phase 3 · monotherapy
—10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
—10 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—2.5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—1.25 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
—0.625 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
Serious AEs
0.7%a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
—Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
4%Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
2.7%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
14.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
7.1%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0.9%10 mgb
NCT00628589 · Phase 3 · monotherapy
show 8 more results
0%5 mg
NCT00628589 · Phase 3 · monotherapy
2.4%10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
2.2%5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%2.5 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%1.25 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
0%0.625 mg
NCT00444028 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
headache 20.3% (placebo 19.7%)
dizziness 17% (placebo 7.5%)
sedation 12.7% (placebo 8.2%)
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 18 more results
dizziness 11.6% (placebo 2.7%)
somnolence 8.3% (placebo 0%)
dry mouth 6.8% (placebo 0%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dizziness 2.6% (placebo 2.7%)
headache 2% (placebo 3.3%)
insomnia 2% (placebo 4.7%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dry mouth 17.9%
dizziness 17.5%
somnolence 14.2%
NCT01207414 · Phase 4 · registry result, not featured evidence
dizziness 22.3%
dry mouth 20.8%
insomnia 9.6%
NCT01207414 · Phase 4 · registry result, not featured evidence
625 mg
injection site pain 66.7%
injection site induration 60%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
625 mg
headache 20%
nasal congestion 20%
anxiety 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
injection site pain 60%
injection site induration 26.7%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
nasal congestion 33.3%
constipation 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
back pain 7.1%
constipation 7.1%
headache 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
insomnia 20%
headache 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
constipation 14.3%
headache 14.3%
anxiety 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
headache 33.3%
insomnia 33.3%
dyspepsia 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
injection site pain 53.3%
headache 26.7%
nasal congestion 26.7%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
nasal congestion 40%
headache 26.7%
oropharyngeal pain 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
pruritus 50%
throat irritation 50%
upper respiratory tract infection 50%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
constipation 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
blood creatine phosphokinase increased 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
dizziness 50%
headache 50%
agitation 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
10 mgb
dizziness 10.6% (placebo 9.6%)
dysgeusia 10.6% (placebo 2.6%)
sedation 10.6% (placebo 9.6%)
NCT00628589 · Phase 3 · monotherapy
show 8 more results
5 mg
sedation 12.9% (placebo 9.6%)
dysgeusia 8.6% (placebo 2.6%)
dizziness 5.2% (placebo 9.6%)
NCT00628589 · Phase 3 · monotherapy
10 mg
sedation 22% (placebo 14%)
dysgeusia 17.1% (placebo 9.3%)
headache 12.2% (placebo 2.3%)
NCT00369577 · Phase 2 · registry result, not featured evidence
5 mg
sedation 13.3% (placebo 14%)
dizziness 11.1% (placebo 9.3%)
dysgeusia 4.4% (placebo 9.3%)
NCT00369577 · Phase 2 · registry result, not featured evidence
10 mg
dizziness 75% (placebo 35.7%)
dysgeusia 75% (placebo 0%)
somnolence 75% (placebo 21.4%)
NCT00444028 · Phase 1 · registry result, not featured evidence
5 mg
dizziness 57.1% (placebo 35.7%)
fatigue 42.9% (placebo 7.1%)
dysgeusia 28.6% (placebo 0%)
NCT00444028 · Phase 1 · registry result, not featured evidence
2.5 mg
dizziness 50% (placebo 35.7%)
nausea 50% (placebo 0%)
dysgeusia 33.3% (placebo 0%)
NCT00444028 · Phase 1 · registry result, not featured evidence
1.25 mg
dizziness 25% (placebo 35.7%)
dysgeusia 25% (placebo 0%)
headache 25% (placebo 14.3%)
NCT00444028 · Phase 1 · registry result, not featured evidence
0.625 mg
dizziness 28.6% (placebo 35.7%)
disturbance in attention 14.3% (placebo 7.1%)
dysgeusia 14.3% (placebo 0%)
NCT00444028 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 21 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Iloperidone (Fanapt)

PANSS Total -12 vs -7.1 placebo score @ 4wk
absolute change · score
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 1 more result
1.1 vs 12.4 placebo score @ 26wk
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
Time to Relapse NA vs 3.25 placebo months @ 26wk
time to event · months
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S 3 vs 3.6 placebo score @ 26wk
absolute value · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
SDS -0.2 vs 1.8 placebo score @ 26wk
absolute change · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-C 2.826 score @ 12wk
absolute value · score
No placebo or comparator arm
NCT01207414 · Phase 4 · registry result, not featured evidence
show 1 more result
2.824 score @ 12wk
NCT01207414 · Phase 4 · registry result, not featured evidence
CGI-S -0.8 score @ 12wk
absolute change · score
No placebo or comparator arm
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
show 3 more results
-0.8 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence

Loxapine (Adasuve)

PANSS-EC -8.6 vs -5.5 placebo score @ 0.0119wk10 mg
absolute change · score
NCT00628589 · Phase 3 · monotherapy
show 1 more result
-8.1 vs -5.5 placebo score @ 0.0119wk5 mg
NCT00628589 · Phase 3 · monotherapy
CGI-I 2.1 vs 2.8 placebo score @ 0.0119wk10 mg
absolute value · score
NCT00628589 · Phase 3 · monotherapy
show 1 more result
2.3 vs 2.8 placebo score @ 0.0119wk5 mg
NCT00628589 · Phase 3 · monotherapy
CGI-I 67% (n=112) vs 35.7% (n=115) placebo @ 0.0119wk10 mg
responder rate · % of participants
NCT00628589 · Phase 3 · monotherapy · converted to % from 75 Participants as posted
show 3 more results
62.5% (n=40) vs 20.9% (n=43) placebo @ 0.0119wk*10 mg
NCT00369577 · Phase 2 · registry result, not featured evidence · converted to % from 25 Participants as posted
56.9% (n=116) vs 35.7% (n=115) placebo @ 0.0119wk*5 mg
NCT00628589 · Phase 3 · monotherapy · converted to % from 66 Participants as posted
48.9% (n=45) vs 20.9% (n=43) placebo @ 0.0119wk*5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted
PANSS-EC -8.56 vs -4.98 placebo PANSS units @ 0.0119wk10 mg
absolute change · PANSS units
NCT00369577 · Phase 2 · registry result, not featured evidence
show 1 more result
-6.71 vs -4.98 placebo PANSS units @ 0.0119wk5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
BARS -2.02 vs -0.93 placebo score @ 0.0119wk10 mg
absolute change · score
NCT00369577 · Phase 2 · registry result, not featured evidence
show 1 more result
-1.53 vs -0.93 placebo score @ 0.0119wk5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence
CGI-I 2.28 vs 3.19 placebo CGI-I Units (7=worse, 1=better) @ 0.0119wk10 mg
absolute value · CGI-I Units (7=worse, 1=better)
NCT00369577 · Phase 2 · registry result, not featured evidence
show 1 more result
2.53 vs 3.19 placebo CGI-I Units (7=worse, 1=better) @ 0.0119wk5 mg
NCT00369577 · Phase 2 · registry result, not featured evidence

Bipolar Disorder

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline

Iloperidone (Fanapt)

Marketed by Vanda Pharmaceuticals

Approved in Bipolar Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2028 · NCT05648591 (registry estimate)

No aligned efficacy figure on record for this race.

Loxapine (Adasuve)

Marketed by Lee's Pharmaceutical and partners

Phase 3 in Bipolar Disordersmall molecule
Partial signal

NCT04148963 · Phase 3 · status unknown

This Phase 3 trial randomly assigned agitated adults with schizophrenia or bipolar disorder to inhaled loxapine or inhaled placebo under quadruple-blind conditions, using change in the PANSS-EC agitation scale at 2 hours as the primary endpoint. No results have been posted, so this remains a well-designed, blinded, placebo-controlled trial whose findings are not yet known. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

No aligned efficacy figure on record for this race.

Results for Bipolar Disorder

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Iloperidone (Fanapt): registry results are on file for Bipolar Disorder, but their comparison mappings are not yet available.

Loxapine (Adasuve): registry results are on file for Bipolar Disorder, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Loxapine (Adasuve)'s landscape